Remmie Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Remmie Health is a private, commercial-stage digital diagnostics company founded in 2019 and headquartered in San Francisco, USA. It has developed a proprietary hardware-plus-software platform centered on an FDA-registered, AI-guided smart otoscope that facilitates remote ENT examinations and integrates with telehealth services. The company generates revenue through direct-to-consumer and likely B2B sales of its device, targeting the growing telehealth and home diagnostics market to reduce the burden of common acute infections. Its value proposition is validated by regulatory clearances (FDA, CE, Health Canada) and reported user metrics showing high satisfaction and cost avoidance.

OtolaryngologyPediatricsTelemedicine

Technology Platform

Integrated hardware-plus-software platform featuring an FDA-registered wireless digital otoscope that connects to smartphones/tablets, paired with a mobile app offering AI-guided image capture, real-time video streaming for telehealth, and secure media sharing.

Opportunities

The rapid growth of telehealth creates a critical need for tools that replicate the in-person physical exam, particularly for high-volume conditions like pediatric ear infections.

There is a significant opportunity to partner with telehealth providers, insurance companies, and employer health plans to distribute the device at scale, demonstrating value through reduced unnecessary visits and lower costs.

Expansion into adjacent visual exam areas (e.g., dermatology, ophthalmology) could further broaden the market.

Risk Factors

Market penetration may be limited if the device remains an out-of-pocket consumer purchase without insurance reimbursement.

The company faces regulatory and liability risks inherent to medical devices, including potential misuse and data privacy concerns.

Competition from other connected otoscope manufacturers and the rapid evolution of smartphone camera technology pose threats to its hardware-centric model.

Competitive Landscape

Remmie competes in the emerging connected home diagnostics space, specifically for ENT. Competitors include other FDA-cleared digital otoscopes (e.g., CellScope Oto, now discontinued, and others from medical device companies) and lower-cost, non-medical grade consumer ear cameras sold on retail platforms. Remmie's key differentiators are its integrated AI-guided capture, real-time streaming capability, and multiple international regulatory clearances, which position it as a more professional-grade solution for telehealth integration.

More companies in Digital Health & Biotech SaaS →More companies in United States →